|
 |
|
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular Pharmaceuticals Market in India 2012
Price: $795.00 (€626.57) ($954.00 (€751.89) Including VAT at 20%)
|
| Publication Date: Apr-2012
Pages: 71
Format: PDF
Publisher: Netscribes (India) Pvt. Ltd.
Sample Pages
Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years.
The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.
An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.
The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.
A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been provided. The section also provides a list of important patent approvals for cardiovascular drugs.
The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Cardiovascular Pharmaceutical industry.
The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the preventive care therapeutic segment will help the companies gain a competitive advantage over the others. Companies can focus on development of such cardiovascular drugs which can be used as preventive medicines, but without any side effects. Also, efficient marketing strategies are required to make both the physicians and the patients aware of such preventive medicines.
Table of Contents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular Pharmaceuticals Market in India 2011
Price: $795.00 (€626.57) ($954.00 (€751.89) Including VAT at 20%)
|
| Publication Date: Sep-2011
Pages: 38
Format: PDF
Publisher: Netscribes (India) Pvt. Ltd.
Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years.
The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.
An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines.
The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.
A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry have been shown. The section also provides a list of important patent approvals for cardiovascular drugs.
The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry.
Table of Contents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Atrial Fibrillation Market Report: 2011 Edition
Price: $700.00 (€551.70) ($840.00 (€662.04) Including VAT at 20%)
|
| Publication Date: Aug-2011
Format: PDF Email
Pages: 32
Publisher: Koncept Analytics
Atrial Fibrillation continues to be the most common heart rhythm disorders ailing the modern society. The incidence and prevalence of atrial fibrillation is on the rise worldwide, mainly due to changes in demographic and lifestyle patterns. This has led to increased consumption of the related drugs and devices which is reflected in the continuous growth of the global atrial fibrillation market as also forecasted by the industry experts. The US and Europe are the two major regions where atrial fibrillation is the most common sustained heart rhythm disorder prevailing among masses and as observed in clinical practice.
The continuous introduction and uptake of new anticoagulants in the atrial fibrillation market and the medical fraternity’s growing support to their increased usage are two major trends being observed in the global atrial fibrillation market. Modern research has produced new hybrid treatment procedures and innovative ablation catheters for the management of atrial fibrillation. Such new products and researches are a development affecting the growth of the atrial fibrillation market all across the globe. Furthermore, improved product and treatment efficacy due to continuous research and development has resulted in their increased adoption by doctors and patients alike. Another major factor driving the growth of the global atrial fibrillation market is the increasing number of elderly and diabetic patients worldwide.
The global atrial fibrillation market is highly competitive with numerous small and large companies located throughout the world. The leading players of the market include St. Jude Medical, Boston Scientific Corporation, Johnson & Johnson's Biosense Webster, C. R. Bard, Medtronic, and Atricure, among others. As the market is characterized by rapid technological advancements, competition in research involving improvement of new and existing products and processes is particularly significant.
The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Insight: Cardiovascular and Metabolic Market Forecast
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 08-Feb-2011
Please click here for more information or to purchase this report at our partner store
In-depth review of the cardiovascular and metabolic markets, including analysis and comparison of key sales trends in the therapy areas of diabetes, dyslipidemia, hypertension and thrombosis for historical (2006–09) and forecast (2010–19) periods. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiovascular and metabolic market overview forecast model
Price: $15,200.00 (€11,979.77) ($18,240.00 (€14,375.73) Including VAT at 20%)
|
| Publication Date: 26-Jan-2010
Please click here for more information or to purchase this report at our partner store
In-depth review of the cardiovascular and metabolic markets, including an analysis of key prescription trends in the main therapy areas between 2005 and 2018, commercial prospects of new agents and sales forecasts to 2018. |
|
|
The Future of Cardiovascular Diagnostics: Impact of technological advances on growth opportunities and future market outlook
Price: $3,835.00 (€3,022.53) ($4,602.00 (€3,627.03) Including VAT at 20%)
|
| Publication Date: 01-Mar-2010
Please click here for more information or to purchase this report at our partner store
Cardiovascular disease (CVD) is one of the leading causes of death in the developed world. The identification and application of novel cardio biomarkers has helped cardiologists to stratify high-risk patients, while the advances in diagnostic imaging have led to improvements in the speed and resolution of images while minimizing the need for invasive procedures, increasing the technology's clinical utility in the detection, diagnosis and treatment of CVD. |
|
|
Analysis of Congenital Heart Diseases Market
Price: $800.00 (€630.51) ($960.00 (€756.62) Including VAT at 20%)
|
| Publication Date: 01-Jun-2010
Format: PDF
Pages: 36
Publisher: Koncept Analytics
Congenital heart disease (COHD) is a heart condition resulting from an abnormality in heart structure or function that is present at birth. Some common congenital heart defects include Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Left Atrial Appendage (LAA) and Patent Ductus Arteriosus (PDA). Ventricular Septal Defects (VSD) is the most common type of congenital heart defects in newborns. The Centre for Disease and Control (CDC) estimates that about 42 out of every 10,000 babies are born with VSD in the United States. Most congenital heart diseases are diagnosed in babies (aged under a year), 30% in children (aged 1-15 years), and 10% in adulthood (16 years and over). The increasing number of addressable patients for congenital heart defects in the U.S, Europe and Japan is a potential opportunity for this market. In addition, the mortality rate attributable to congenital defects has been declining over the last few years. Rise in survival rates of COHD patients till adulthood, evolution of new diagnostic techniques, increasing consumer income and rising number of cardiologists and medical practitioners are the main factors that will be driving the market in future. The congenital heart defect market is characterized by few competitors due to high entry barriers. AGA Medical is the market leader in the structural heart repair market. The other major players include NMT Medical, St. Jude medical, GORE Medical, Occlutech and Coherex. The current report analyzes the market size and segmentation of the congenital heart diseases market. The various drivers, opportunities and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Coronary Stent Market Report
Price: $850.00 (€669.92) ($1,020.00 (€803.91) Including VAT at 20%)
|
| Publication Date: 01-May-2009
Format: PDF Email
Pages: 41
Publisher: Koncept Analytics
Heart diseases or heart attacks are nowadays becoming more and more common, and in fact, are one of the largest killing diseases worldwide. Heart attack is caused by narrowing of or any blockage in the coronary arteries, which supply blood to heart muscles. Stents used in the coronary arteries to keep them open are called coronary stents, and due to intensity and the rate of increase in the disease are also gaining importance. The coronary stents market has come a long way and its journey has been marked by growth as well as decline phases. Since the advent of drug-eluting stents in the early 2000, the coronary stent market witnessed a spurt in growth. The years 2006 and 2007 saw a significant decline in market revenues due to release of some adverse clinical trial data that raised questions about the efficacy and safety of drug-eluting stents. 2008 again showed some stability. The Percutaneous coronary intervention (PCI) procedures and the use of drug-eluting stents (DES) in those procedures, implying the DES penetration rate are the main indicators of growth of the DES market or the coronary market at large. Bare metal stents (BMS) and drug-eluting stents are the two types of coronary stents. Before the advent of DES, BMS were the only type of stents available and hence covered the entire market. Since entry of DES, the market has shifted almost entirely towards DES. The report analyzes the coronary stent market from two perspectives. One is from the point of products, i.e., BMS and DES market size, growth rate and market share. Second is the size of the main regional stents market, like, the US, Europe, Japan and Asia Pacific. The main factors driving the growth of the market are also discussed along with the new developments in the market. The competitive landscape of the market is also analyzed. By combining SPSS Inc.Ís data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
Worldwide Heart Valve Market Report: 2009 Edition
Price: $800.00 (€630.51) ($960.00 (€756.62) Including VAT at 20%)
|
| Publication Date: 01-May-2009
Format: PDF Email
Pages: 32
Publisher: Koncept Analytics
The two major segments of heart valve market ? tissue valve & mechanical valve ? both have pros and cons. Tissue valves have a lower risk for clotting but they are not durable for long-term usage compared to mechanical valves. Mechanical valves are more durable, but require anti-coagulant drugs to prevent blood clots. Tissue valve are ideal for older patients. The mechanical valve market is expected to continue to grow in the low single digits while tissue valve market is growing at mid-single digit rates. Global mechanical valve unit sales have declined significantly over the last five years due to growth of tissue valves. Overall growth would be driven by the expansion of cardiac surgery in countries such as China, India and Eastern European nations. Edwards Life Sciences is the leader in global tissue valve market while in the mechanical valve segment, St. Jude Medical is the global market leader. Heart valve companies are targeting the transcatheter valve segment, which presents an attractive market opportunity. The technology, involving less invasive approach, is ideal for high risk patients. In the long-term, transcatheter valves are expected to represent an increasing share of the heart valve market. The report analyzes the heart valve market. It analyzes the worldwide and the US market. Apart from providing a competitive landscape of the market, the report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major product segments in the heart valve market. By combining SPSS Inc.Ís data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
Price: $800.00 (€630.51) ($960.00 (€756.62) Including VAT at 20%)
|
| Publication Date: 01-May-2009
Format: PDF Email
Pages: 35
Publisher: Koncept Analytics
In the present era, use of tobacco, polluted environment, poverty and aging population have become a major threat; all these factors account for a major cause of deaths by COPD. Market for COPD medication is growing with increasing prevalence rate worldwide and it has become the fourth leading cause of death. The number of people with COPD varies throughout world. Cape Town has the highest prevalence of COPD, while Hanover has the lowest prevalence. In United States, its prevalence is high and geographically, its prevalence in the Southern part of the country is highest and the Northeastern part has the lowest prevalence rate. With increasing rate of COPD patients, the economic cost is also increasing, which leads to the highest economic cost out of all the lung diseases in United States. Spiriva is the leading medication for the disease while rest of the medicines market is expected to decline in future with the effect of new developments and increasing competition. At present Advair has also a good hold in the market. Inhalers demand is high for COPD and there are few oral medicines available. The present report analyses worldwide COPD market with prevalence of the disease in major parts of the world. It talks about United States and Australian market for the medication of COPD and mortality and death rates. Economic cost is also an important segment of the report in which we have discussed US and Australian markets. There are many factors driving the industry which are discussed in growth drivers. In future trends we have discussed the projected market condition, which may help in forming strategies. The report also talks about the future outlook of the industry and its growth. By combining SPSS Inc.Ís data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
Growth Opportunities for LVAD in Heart Failure Market
Price: $750.00 (€591.11) ($900.00 (€709.33) Including VAT at 20%)
|
| Publication Date: 01-Feb-2010
Format: PDF Email
Pages: 36
Publisher: Koncept Analytics
Heart failure (HF) occurs when oxygenated blood is not fully cleared from the lungs, inhibiting blood flow to the rest of the body. Once a patient starts down the path of heart failure, the underlying disease causes the condition to actually accelerate. Moreover, many symptoms associated with HF can be treated, but often the underlying functional impairment of the heart cannot. As a result of blood not being cleared fully, the left ventricle tries to pump additional blood and becomes overworked causing the left ventricle to expand and the heart to become more constricted, further preventing adequate blood flow. Heart transplantation, currently, is the only curative treatment option which ultimately provides the best recovery of cardiac function. This treatment option has severe limitations, one due to limited availability of donor hearts and secondly, ineligibility of many patients for transplantation due to many factors. Drug treatment and pacing devices also do not halt the progression of the disease. Other devices and cell based therapy are either in the early stages of development or are otherwise not achieving the desired results. Due to these factors, VADs are gaining increasing clinical recognition as a viable long term treatment option. The population of those suffering from diagnosed congestive heart failure has been increasing while the number of donor hearts available are on a decrease, implying good growth prospects for left ventricular assist devices (LVAD) market. The main application of LVAD is currently for the Bridge-to-Transplant (BTT) market and not so much under the Destination Therapy (DT) market, However, DT application is expected to gain penetration in the near future as efforts are currently on to gain FDA approval for DT application of LVADs for the DT market. Bridge-to-Decision (BTD), which is not a formal indication established by the FDA, would also open new growth avenues for LVADs. The report provides an overview of the heart failure and its treatments options and LVAD as one of the options. The market size and growth in the LVAD market is explained in details, along with the associated end stage heart failure cost and LVAD reimbursement. The growth drivers and challenges are also discussed. The key players are profiled with their strategies for the market and the competition among the players is also discussed in detail.
Table of Contents/List of Tables/List of Figures |
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own